Principal results comparing use of an antimicrobial resistance point-of-care test (AMR POCT) for ciprofloxacin (scenario 3a) or penicillin resistance (scenario 3b) against current testing practice (standard laboratory testing, no POCT) for the management of gonorrhoea (scenario 1), assuming the current attendance at genitourinary medicine clinic annually
| Heterosexual male | MSM | Female | Overall | |
| Considering use of POCT test for ciprofloxacin resistance | ||||
| Annual ceftriaxone treatments | ||||
| Current (scenario 1) | 7690 | 17 691 | 8050 | 33 431 |
| AMR POCT (scenario 3a) | 2188 | 7933 | 1257 | 11 378 |
| Reduction under scenario 3a | 5502 | 9759 | 6793 | 22 054 |
| Percentage reduction in ceftriaxone | 72 | 55 | 84 | 66 |
| Proportion treated same day (%) | ||||
| Current (scenario 1) | 68 | 63 | 21 | 54 |
| AMR POCT (scenario 3a) | 100 | 100 | 100 | 100 |
| Increase under scenario 3a | 32 | 37 | 79 | 46 |
| Mean time to treatment (days) | ||||
| Current (scenario 1) | 1.5 | 1.8 | 3.9 | 2.2 |
| AMR POCT (scenario 3a) | 0.0 | 0.0 | 0.0 | 0.0 |
| Reduction under scenario 3a | 1.5 | 1.8 | 3.9 | 2.2 |
| Persons lost to follow-up (untreated) | ||||
| Current (scenario 1) | 125 | 338 | 329 | 792 |
| AMR POCT (scenario 3a) | 0 | 0 | 0 | 0 |
| Considering use of POCT test for penicillin resistance | ||||
| Annual ceftriaxone treatments* | ||||
| Current (scenario 1) | 7690 | 17 691 | 8050 | 33 431 |
| AMR POCT (scenario 3b) | 1407 | 4688 | 838 | 6932 |
| Reduction under scenario 3b | 6283 | 13 004 | 7212 | 26 499 |
| Percentage reduction in ceftriaxone | 82 | 74 | 90 | 79 |
*All other outcomes same as for use of POCT for ciprofloxacin resistance. Results for strategy 2 not shown: equivalent to strategy 3 except for choice of antibiotic treatment. Results for 3b also equivalent to 3a for outcomes except reduction in ceftriaxone treatments.
MSM, men who have sex with men.